AstraZeneca’s Tagrisso to lead lung cancer small molecule market with over $7 billion sales by 2029, says GlobalData
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Combination shows consistent benefit across prespecified post-progression outcomes
The company has received five final approvals
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
Subscribe To Our Newsletter & Stay Updated